Clinical trials
Lung Cancer Patients clinical trials
Below are recruiting lung cancer patients clinical trials, each written for real people, not researchers. We’re tracking 1,877 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05924841RecruitingPhase 2
Study drugs for advanced small cell lung cancer after prior treatments
This Phase 2 trial tests how well two study drugs (and a combination of them) work in people with extensive-stage small cell lung cancer. It’s mainly for patients whose cancer has come back or who couldn’t tolerate at least some standard treatments, and it aims to see if treatment can shrink tumors and be tolerable.
Changchun, JilinAges 18–75 - NCT05933239RecruitingPhase 2
PET-like scan using a special protein in lung cancer
This Phase 2 study tests whether a new imaging medicine (a radiopharmaceutical) can highlight immune cells called macrophages in people with non-small cell lung cancer. It may help doctors better “see” and evaluate tumor tissue before a surgical biopsy or removal.
Jette, Brussels CapitalAges 18 years+ - NCT04900935Recruiting
Survivorship and palliative care planning for metastatic lung cancer
This study tests a more patient-centered way to plan survivorship care and comfort (palliative) care for people with metastatic lung cancer. It may help you get support that matches your goals, especially alongside your current targeted treatment.
Boston, MassachusettsAges 18 years+ - NCT05886439RecruitingPhase 1/Phase 2
Study drug plus PD-1 or PD-L1 for lung cancer
This Phase 1/2 trial tests a new treatment called LK101 combined with a PD-1 or PD-L1 antibody for advanced lung cancer. It may help shrink tumors and improve control of the disease, especially after prior anti–PD-1/PD-L1 treatment has stopped working.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05889546Recruiting
Rapid autopsy protocol for small cell lung cancer patients
This study looks at a planned, faster way to collect information from patients’ bodies after death who have small cell lung cancer. The goal is to better understand the disease and potentially improve future care, with consent from the patient or their authorized representative.
Indianapolis, IndianaAges 18 years+ - NCT05903092RecruitingPhase 2
Monalizumab plus durvalumab for small cell lung cancer
This Phase 2 trial tests whether adding monalizumab to durvalumab (two immune-targeting medicines) can improve outcomes in people with small cell lung cancer. You may be able to join if you have certain stage of small cell lung cancer and have not had the specific prior treatments the study allows.
Indianapolis, IndianaAges 18 years+ - NCT05568212RecruitingPhase 2
Trial of immune combination versus standard care for NSCLC relapse
This Phase 2 trial studies an immune-based drug combination compared with standard care for lung cancer that has come back after chemoradiation and durvalumab. It aims to improve control of the cancer after durvalumab is no longer working.
Roma, RMAges 18 years+ - NCT04063501Recruiting
Study of gut microbes during immunotherapy for lung cancer
This trial studies how gut bacteria (the microbiome) and the body’s immune signs change over time while you receive PD-1–based immunotherapy for advanced, unresectable non–small cell lung cancer. The goal is to learn which immune and microbial patterns might relate to how well treatment works and how patients respond.
New York, New YorkAges 18–100 - NCT05802186Recruiting
AI-guided radiation plan for lung cancer tumors
This study uses an AI tool to help plan how doctors deliver focused radiation to lung tumors. It may help make radiation targeting more precise and support treatment safety for people with primary or limited metastatic lung cancer.
Chicago, IllinoisAges 18 years+ - NCT05800587RecruitingPhase 2
Reduced-dose chemotherapy for advanced lung cancer
This trial studies a lower (reduced) dose of chemotherapy in people with advanced lung cancer who may not tolerate standard treatment. It aims to see if the treatment still works while being safer for “compromised” patients.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05746325Recruiting
Tumor-pulse device for spinal cancer fluid spread
This trial tests whether Tumor Treating Fields (a non-surgical device that delivers treatment signals to cancer cells through the scalp/skin) can help people whose breast or lung cancer has spread into the fluid around the spine and brain. It focuses on people who have cancer cells found in spinal fluid and can safely use the device most of the day.
Jacksonville, FloridaAges 18 years+ - NCT05696782RecruitingPhase 2
Durvalumab after chemoradiation for stage III lung cancer
This trial tests giving durvalumab (an immune therapy) soon after standard chemotherapy and radiation for stage II–III non-small cell lung cancer that cannot be removed by surgery. The goal is to see if this “quick start” approach improves outcomes compared with waiting longer to begin durvalumab.
Charlotte, North CarolinaAges 18 years+ - NCT05681780RecruitingPhase 1
CD40L-treated immune cells for advanced lung cancer with certain gene changes
This Phase 1 study tests a lab-made immune cell treatment (TIL) boosted with CD40L, plus nivolumab, for stage IV or returning non-small cell lung cancer with specific gene changes (EGFR, ALK, ROS1, or HER2). It aims to help your immune system attack the cancer after it has grown despite standard treatments.
Tampa, FloridaAges 18 years+ - NCT04944030Recruiting
Study collects health data for metastatic lung cancer patients
This study collects medical information and test results from people with lung cancer that has spread (or cannot be cured with local treatment). It does not test a new drug; it helps researchers better understand patients’ health and care needs over time.
AngersAges 18 years+ - NCT05657873RecruitingPhase 2
Targeted radiation for metastatic lung cancer with liver spread
This trial studies whether adding targeted radiation to the liver (small-area, high-precision radiation) can help people with stage IV non-small cell lung cancer. Participants also start standard “anti–PD-1/PD-L1” immunotherapy (with chemotherapy in some cases).
Miami, FloridaAges 18 years+ - NCT05632913Recruiting
Radiation seeds trial for recurring lung cancer in the chest
This trial tests a treatment that places tiny radiation “seeds” inside/near the chest tumor to treat recurrent lung cancer. It may help people whose cancer has come back and can be safely reached by the radiation device.
JerusalemAges 18 years+ - NCT05607108RecruitingPhase 2
Study drug for advanced lung cancer with a specific genetic change
This Phase 2 trial tests ZEN003694 in people with squamous (a type of) lung cancer that has returned or spread. It’s designed for tumors that have a certain gene change, and it may offer a new treatment option after prior chemotherapy and immunotherapy.
Basking Ridge, New JerseyAges 18 years+ - NCT05624996RecruitingPhase 3
Targeted high-dose radiation added to standard lung cancer treatment
This trial tests whether adding high-dose, targeted radiation to the usual treatment helps people with locally advanced, non-operable lung cancer live longer or better control the cancer. It may help shrink tumors in the chest and improve outcomes when surgery can’t be done.
Birmingham, AlabamaAges 18 years+ - NCT05611034RecruitingPhase 1
Testing a lung treatment for colorectal cancer spread to lungs
This Phase 1 trial tests a targeted treatment delivered to the lungs for colorectal cancer that has spread to the lungs. It aims to see if the approach is safe and can reach lung tumors, especially when there are multiple lung lesions.
Toronto, OntarioAges 18–70 - NCT05570825RecruitingPhase 2
Study drug SX-682 with pembrolizumab for advanced lung cancer
This trial tests SX-682 plus pembrolizumab (an immunotherapy) to treat metastatic or recurrent non-small cell lung cancer (NSCLC). It aims to see how well the combination works and whether it can shrink or control the cancer in people whose tumors have enough PD-L1.
Seattle, WashingtonAges 18 years+ - NCT05557474Recruiting
Test of a lung cancer prognosis kit after early tumor removal
This study tests a lab “prognosis kit” to better predict how early-stage lung cancer may progress after the tumor has been fully removed. You may be asked to provide tumor samples and possibly blood/body fluid samples so researchers can validate the kit.
Taichung, TaiwanAges 20 years+ - NCT05572944Recruiting
Using family risk to predict lung cancer in never-smokers
This study builds and tests risk prediction tools for lung cancer in people who have never smoked, using information from family history. If it works, it may help doctors identify who might need closer screening earlier.
Taichung, TaiwanAges 20–80 - NCT03556228RecruitingPhase 1/Phase 2
Tested medicine for tumors with TrkA changes, alone or with pembrolizumab
This early-phase study tests VMD-928, a targeted cancer medicine, for cancers that have TrkA-related tumor changes. It may be given by itself or with pembrolizumab to see if it can shrink tumors when standard treatments have not worked.
Santa Rosa, CaliforniaAges 18–80 - NCT05493566RecruitingEarly Phase 1
Low-dose IL-2 plus pembrolizumab for stage IV lung cancer
This early-phase study tests whether low-dose IL-2 combined with pembrolizumab can help treat stage IV non-small cell lung cancer that has not had prior advanced treatment. It may be an option if your tumor has certain immune-marker findings (PD-L1) and you meet safety requirements.
Atlanta, GeorgiaAges 18 years+
Hear when a new Lung Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer patients?
- Yes. Clin2 currently lists 1,877 recruiting lung cancer patients studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer patients trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer patients trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.